- Simulations Plus Receives New FDA Grant Award (09/21/2023)
- Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment (08/15/2023)
- Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses (04/18/2023)
- Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology (03/28/2023)
- Simulations Plus and Global Agrochemicals Leader to Collaborate on Machine Learning Models (02/16/2023)